Our Team

Success depends on the right combination of expertise and experience. Our project teams are hand-picked to meet your needs.

Judy Ashworth, MD

Senior Vice President

Guiding the clinical development of CNS-active drugs in a challenging and rapidly evolving regulatory environment

Jack Henningfield, PhD

Vice President, Research, Health Policy, and Abuse Liability

Leading development and regulatory strategy for new treatments for neurological and psychiatric disorders with high unmet needs

Ryan Lanier, PhD

Director, Clinical Development and Abuse Liability

Utilizing extensive clinical and nonclinical research experience to strategically guide the development of new CNS-active drugs

Daniel Wang

Director, Cannabinoids and New Dietary Ingredients

Helping clients advance their ideas and bring meaningful innovative products to consumers

Marilyn Huestis, PhD

Senior Science and Policy Advisor, Clinical Pharmacology and Toxicology, Cannabinoid and Other CNS-Active Pharmacotherapies

Applying excellence in clinical and forensic toxicology to CNS-active drug and compound development and regulatory pathways

Speak to an expert.